Subscribe Now Subscribe Today
Research Article
 

Adverse Effects of Statins



Anna Jamroz-Wisniewska and Jerzy Bettowski
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail
ABSTRACT

Statins are competitive inhibitors of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis pathway, which converts HMG-CoA to mevalonate. Statins lower plasma Low Density Lipoprotein (LDL)-bound cholesterol by causing intracellular cholesterol depletion and upregulating the expression of LDL receptors. Apart from cholesterol, mevalonate is also used as the substrate for the synthesis of nonsteroid isoprenoids including farnesylpyrophosphate, geranylgeranylpyrophosphate (both attached to small GTP-binding proteins by protein prenyltransferases), coenzyme Q, dolichol, isopentenylpyrophosphate, etc. Inhibiting the synthesis of these nonsteroid isoprenoids results in so called "pleiotropic" effects of statins which are independent of cholesterol lowering. Although statins are generally well-tolerated, adverse effects may occur in some patients. Myopathy is the most frequent side effect of statins. Other less common include peripheral neuropathy, hepatotoxicity, increased risk of cataract and, according to some studies, increased risk of breast cancer. Some studies suggest that under specific experimental conditions statins may exert detrimental effects also on processes which are generally believed to be favorably modified by these drugs, e.g. vascular reactivity, myocardial performance or atherogenesis. In this review currently recognized mechanisms through which statins could induce side effects are discussed.

Services
Related Articles in ASCI
Search in Google Scholar
View Citation
Report Citation

 
  How to cite this article:

Anna Jamroz-Wisniewska and Jerzy Bettowski , 2005. Adverse Effects of Statins. International Journal of Pharmacology, 1: 210-225.

DOI: 10.3923/ijp.2005.210.225

URL: https://scialert.net/abstract/?doi=ijp.2005.210.225

REFERENCES

1:  Shepherd, J., S.M. Cobbe, I. Ford, C.G. Isles and A.R. Lorimer et al., 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N. Engl. J. Med., 333: 1301-1307.
PubMed  |  

2:  Downs, J.R., M. Clearfield, S. Weis, E. Whitney and D.R. Shapiro et al., 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air force/Texas coronary atherosclerosis prevention study. J. Am. Med. Assoc., 279: 1615-1622.
CrossRef  |  PubMed  |  Direct Link  |  

3:  Dallner, G. and P.J. Sindelar, 2000. Regulation of ubiquinone metabolism. Free Radic. Biol. Med., 29: 285-294.
PubMed  |  

4:  Crane, F.L., 2001. Biochemical functions of coenzyme Q10. J. Am. College Nutr., 20: 591-598.
Direct Link  |  

5:  Willis, R.A., K. Folkers, J.L. Tucker, C.Q. Ye, L.J. Xia and H. Tamagawa, 1990. Lovastatin decreases coenzyme Q levels in rats. Proc. Natl. Acad. Sci. USA., 87: 8928-8930.

6:  Rousseau, G., C. Desrosiers and F. Varin, 1998. A comparison of the effects of lovastatin and pravastatin on ubiquinone tissue levels in rats. Curr. Therapeuti. Res., 59: 666-679.

7:  Folkers, K., P. Langsoen, R. Willis, P. Richardson, L.J. Xia, C.Q. Ye and H. Tamagawa, 1990. Lovastatin decreases coenzyme Q levels in humans. Proc. Natl. Acad. Sci. USA, 87: 8931-8934.
PubMed  |  Direct Link  |  

8:  De Pinieux, G., P. Chariot, M. Ammi-Said, F. Louarn and J.L. Lejonc et al., 1996. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br. J. Clin. Pharmacol., 42: 333-337.

9:  Kaikkonen, J., K. Nyyssonen, T.P. Tuomainen, U. Ristonmaa and J.T. Salonen, 1999. Determinants of plasma coenzyme Q10 in humans. FEBS Lett., 443: 163-166.

10:  Rundek, T., A. Naini, R. Sacco, K. Coates and S. Di-Mauro, 2004. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch. Neurol., 61: 889-892.
PubMed  |  

11:  Passi, S., A. Stancato, E. Aleo, A. Dmitrieva and G.P. Littarru, 2003. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors, 18: 113-124.
PubMed  |  

12:  Satoh, K. and K. Ichihara, 1995. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts. Eur. J. Pharmacol., 292: 271-275.

13:  Satoh, K., A. Yamato, T. Nakai, K. Hoshi and K. Ichihara, 1995. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br. J. Pharmacol., 116: 1894-1898.
Direct Link  |  

14:  Goli, A.K., S.A. Goli, R.P. Jr. Byrd and T.M. Roy, 2002. Simvastatin-induced lactic acidosis: A rare adverse reaction Clin. Pharmacol. Therapeut., 72: 461-464.
PubMed  |  

15:  Levy, B.D., N.A. Petasis and C.N. Serhan, 1997. Polyisoprenyl phosphates in intracellular signalling. Nature, 389: 985-990.

16:  Hattori, Y., N. Nakanishi and K. Kasai, 2002. Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc. Res., 54: 649-658.
Direct Link  |  

17:  Ikeda, U., M. Shimpo, M. Ikeda, S. Minota and K. Shimada, 2001. Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. J. Cardiovasc. Pharmacol., 38: 69-77.

18:  Kishi, T., Y. Hirooka, Y. Mukai, H. Shimokawa and A.Takeshita, 2003. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J. Hypertens., 21: 379-386.
Direct Link  |  

19:  Fisslthaler, B., U.R. Michaelis, V. Randriamboavonjy, R. Busse and I. Fleming, 2003. Cytochrome P450 epoxygenases and vascular tone: Novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. Biochim. Biophys. Acta, 1619: 332-339.

20:  Pizzi, C., O. Manfrini, F. Fontana and R. Bugiardini, 2004. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: Role of superoxide dismutase activity. Circulation, 109: 53-58.

21:  Vecchione, C. and R.P. Brandes, 2002. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circulation Res., 91: 173-179.

22:  Sinzinger, H., F. Chehne and G. Lupattelli, 2002. Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy. Drug Saf., 25: 877-883.
Direct Link  |  

23:  Moosmann, B. and C. Behl, 2004. Selenoprotein synthesis and side effects of statins. Lancet, 363: 892-894.

24:  Moosmann, B. and C. Behl, 2004. Selenoproteins, cholesterol-lowering drugs and the consequences: Revisiting of the mevalonate pathway. Trends Cardiovasc. Med., 14: 273-281.

25:  Smith, P.F., S.J. Grossman, R.J. Gerson, L.R. Gordon and J.G. Deluca et al., 1991. Studies on the mechanism of simvastatin-induced thyroid hypertrophy and follicular cell adenoma in the rat. Toxicol. Pathol., 19: 197-205.

26:  Demke, D.M., 1989. Drug interaction between thyroxine and lovastatin. N. Engl. J. Med., 321: 1341-1342.

27:  Sinzinger, H., R. Wolfram and B.A. Peskar, 2002. Muscular side effects of statins. J. Cardiovasc. Pharmacol., 40: 163-171.

28:  Koumis, T., J.P. Nathan, J.M. Rosenberg and L.A. Cicero, 2004. Strategies for the prevention and treatment of statin-induced myopathy: Is there a role for ubiquinone supplementation? Am. J. Health Syst. Pharm., 61: 515-519.
Direct Link  |  

29:  Rosenson, R.S., 2004. Current overview of statin-induced myopathy. Am. J. Med., 116: 408-416.
Direct Link  |  

30:  Thompson, P.D., P. Clarkson and R.H. Karas, 2003. Statin-associated myopathy. J. Am. Med. Assoc., 289: 1681-1690.
PubMed  |  Direct Link  |  

31:  Jamal, S.M., M.J. Eisenberg and S. Christopoulos, 2004. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am. Heart J., 147: 956-965.

32:  Psaty, B.M., C.D. Furberg, W.A. Ray and N.S. Weiss, 2004. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: Use of cerivastatin and risk of rhabdomyolysis. J. Am. Med. Assoc., 292: 2622-2631.

33:  Graham, D.J., J.A. Staffa, D. Shatin, S.E. Andrade and S.D. Schech et al., 2004. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. J. Am. Med. Assoc., 292: 2585-2590.

34:  Prueksaritanont, T., C. Tang, Y. Qiu, L. Mu, R. Subramanian and J.H. Lin, 2002. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos., 30: 1280-1287.
CrossRef  |  Direct Link  |  

35:  Chang, J.T., J.A. Staffa, M. Parks and L. Green, 2004. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol. Drug Safety, 13: 417-426.

36:  Nakahara, K., M. Kuriyama, Y. Sonoda, H. Yoshidome and H. Nakagawa et al., 1998. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological, electrophysiological and biochemical study. Toxicol. Applied Pharmacol., 152: 99-106.
Direct Link  |  

37:  Schaefer, W.H., J.W. Lawrence, A.F. Loughlin, D.A. Stoffregen and L.A. Mixson et al., 2004. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol. Applied Pharmacol., 194: 10-23.
Direct Link  |  

38:  Laaksonen, R., K. Jokelainen, J. Laakso, T. Sahi, M. Harkonen, M.J. Tikkanen and J.J. Himberg, 1996. The effect of simvastatin treatment on natural antioxidants in low density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am. J. Cardiol., 77: 851-854.

39:  Laaksonen, R., K. Jokelainen, T. Sahi, M.J. Tikkanen and J.J., Himberg, 1995. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin. Pharmacol. Therapeut., 57: 62-66.

40:  Paiva, H., J. Laakso, T. Lehtimaki and R. Laaksonen, 2002. Agressive lipid-lowering with statins and skeletal muscle ubiquinone: A randomised, controlled trial. Atheroscler. Suppl., 3: 147-148.

41:  Sinzinger, H., G. Lupattelli, F. Chehne, A. Oguogho and C.D. Furberg, 2001. Isoprostane 8-epi-PGF2α is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J. Clin. Pharm. Therapeut., 26: 303-310.
Direct Link  |  

42:  Sinzinger, H., 2000. Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK-elevation? Atherosclerosis, 149: 225-225.
PubMed  |  

43:  Nakagawa, H., T. Mutoh, T. Kumano and M. Kuriyama, 2001. Tyrosine phosphorylation of the catalytic subunit p110 of phosphatidylinositol-3 kinase induced by HMG-CoA reductase inhibitor inhibits its kinase activity in L6 myoblasts. FEBS Lett., 508: 53-56.
Direct Link  |  

44:  Flint, O.P., B.A. Masters, R.E. Gregg and S.K. Durham, 1997. Inhibition of cholesterol synthesis by squalene synthase. Toxicol. Applied Pharmacol., 145: 91-98.

45:  Pasternak, R.C., S.C. Jr. Smith, C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman and C. Lenfant, 2002. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J. Am. College Cardiol., 40: 567-572.
Direct Link  |  

46:  Chariot, P., R. Abadia, D. Agnus, C. Danan, C. Charpentier and R.K. Gherardi, 1993. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am. J. Med., 94: 109-110.

47:  Backes, J.M. and P.A. Howard, 2003. Association of HMG-CoA reductase inhibitors with neuropathy. Ann. Pharmacother., 37: 274-278.
CrossRef  |  

48:  Lo, Y.L., T.H. Leoh, L.M. Loh and C.E. Tan, 2003. Statin therapy and small fibre neuropathy: A serial electrophysiological study. J. Neurol. Sci., 208: 105-108.
Direct Link  |  

49:  Gaist, D., U. Jeppesen, M. Andersen, L.A. Garcia Rodriguez, J. Hallas and S.H. Sindrup, 2002. Statins and risk of polyneuropathy: A case-control study. Neurology, 58: 1333-1337.
Direct Link  |  

50:  Gaist, D., L.A. Garcia-Rodriguez, C. Huerta, J. Hallas and S.H. Sindrup, 2001. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur. J. Clin. Pharmacol., 56: 931-933.
Direct Link  |  

51:  Muldoon, M.F., S.D. Barger, C.M. Ryan, J.D. Flory, J.P. Lehoczky, K.A. Matthews and S.B. Manuck, 2000. Effects of lovastatin on cognitive function and psychological well-being. Am. J. Med., 108: 538-546.
CrossRef  |  PubMed  |  Direct Link  |  

52:  Wagstaff, L.R., M.W. Mitton, B.M. Arvik and P.M. Doraiswamy, 2003. Statin-associated memory loss: Analysis of 60 case reports and review of the literature. Pharmacotherapy, 23: 871-880.
CrossRef  |  PubMed  |  Direct Link  |  

53:  King, D.S., A.J. Wilburn, M.R. Wofford, T.K. Harrell, B.J. Lindley and D.W. Jones, 2003. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy, 23: 1663-1667.
PubMed  |  

54:  Matthies, H., S. Schulz, V. Hollt and M. Krug, 1997. Inhibition by compactin demonstrates a requirement of isoprenoid metabolism for long-term potentiation in rat hippocampal slices. Neuroscience, 79: 341-346.

55:  Gervais, M., S. Pons, A. Nicoletti, C. Cosson, J.F. Giudicelli and C. Richer, 2003. Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice. Arterioscler Thromb. Vascular Biol., 23: 183-189.
PubMed  |  

56:  Parker, R.A., Q. Huang and B. Tesfamariam, 2003. Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Atherosclerosis, 169: 19-29.
Direct Link  |  

57:  Roullet, J.B., H. Xue, A.S. Pappu, C. Roullet, S. Holcomb and D.A. McCarron, 1993. Mevalonate availability and cardiovascular functions. Proc. Natl. Acad. Sci. USA., 90: 11728-11732.

58:  Roullet, J.B., H. Xue, C.M. Roullet, W.S. Fletcher, M.J. Cipolla, C.T. Harker and D.A. McCarron, 1995. Mevalonate availability affects human and rat resistance vessel function. J. Clin. Invest., 96: 239-244.

59:  Roullet, J.B., H. Xue, J. Chapman, P. McDougal, C.M. Roullet and D.A. McCarron, 1996. Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J. Clin. Invest., 97: 2384-2390.

60:  Luft, U.C., R. Bychkov, M. Gollasch, V. Gross and J.B. Roullet et al., 1999. Farnesol blocks the L-type Ca2+ channel by targeting the α 1C subunit. Arterioscler. Thromb. Vascular Biol., 19: 959-966.

61:  Sawamura, M., Y. Nara and Y. Yamori, 1992. Liver mevalonate 5-pyrophosphate decarboxylase is responsible for reduced serum cholesterol in stroke-prone spontaneously hypertensive rat. J. Biol. Chem., 267: 6051-6055.

62:  Martinez-Castelao, A., J.M. Grinyo, C. Fiol, M.J. Castineiras and I. Hurtado et al., 1999. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients. Kidney Intl., 56: S231-S234.
CrossRef  |  Direct Link  |  

63:  Lankin, V.Z., A.K. Tikhaze, G.G. Konovalova, V.S. Tutunov and N.V. Medvedeva et al., 2002. Intensification of free radical oxidation of low density lipoproteins in the plasma of patients with ischemic heart disease receiving beta-hydroxy-beta-methylglutaryl-coenzyme a reductase inhibitor cerivastatin and inhibition of low density lipoprotein peroxidation with antioxidant probucol. Bull. Exp. Biol. Med., 134: 39-42.
PubMed  |  

64:  Palomaki, A., K. Malminiemi and T. Metsa-Ketela, 1997. Enhanced oxidizability of ubiquinol and α‐tocopherol during lovastatin treatment. FEBS Lett., 410: 254-258.
CrossRef  |  Direct Link  |  

65:  Palomaki, A., K. Malminiemi, O. Malminiemi and T. Solakivi, 1999. Effects of lovastatin therapy on susceptibility of LDL to oxidation during α-tocopherol supplementation. Arterioscler. Thromb. Vasc. Biol., 19: 1541-1548.
CrossRef  |  Direct Link  |  

66:  Lankin, V.Z., A.K. Tikhaze, V.V. Kukharchuk, G.G. Konovalova and O.I. Pisarenko et al., 2003. Antioxidants decrease the intensification of low density lipoprotein in vivo peroxidation during therapy with statins. Mol. Cell Biochem., 249: 129-140.
CrossRef  |  

67:  Palomaki, A., K. Malminiemi, T. Solakivi and O. Malminiemi, 1998. Ubiquinone supplementation during lovastatin treatment: Effect on LDL oxidation ex vivo. J. Lipid Res., 39: 1430-1437.

68:  Vasankari, T., M. Ahotupa, J. Viikari, I. Nuotio and T. Vuorenmaa et al., 2005. Effects of statin therapy on circulating conjugated dienes, A measure of LDL oxidation. Atherosclerosis, 179: 207-209.
Direct Link  |  

69:  Wong, J., C.M. Quinn and A.J. Brown, 2004. Statins inhibit synthesis of an oxysterol ligand for the liver X receptor in human macrophages with consequences for cholesterol flux. Arterioscler. Thromb. Vascular Biol., 24: 2365-2371.
Direct Link  |  

70:  Gouedard, C., N. Koum-Besson, R. Barouki and Y. Morel, 2003. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol., 63: 945-956.
Direct Link  |  

71:  Getz, G.S. and C.A.Reardon, 2004. Paraoxonase, a cardioprotective enzyme: Continuing issues. Curr. Opin. Lipidol., 15: 261-267.
PubMed  |  

72:  Beltowski, J., G. Woycicka, M. Mydlarczyk and A. Jamroz, 2002. Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat. Polish J. Pharmacol., 54: 143-150.
Direct Link  |  

73:  Beltowski, J., G. Wojcicka and A. Jamroz, 2002. Differential effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat. Polish J. Pharmacol., 54: 661-671.
PubMed  |  

74:  Beltowski, J., G. Wojcicka and A. Jamroz, 2004. Effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities. J. Cardiovasc. Pharmacol., 43: 121-127.
Direct Link  |  

75:  Ruiz-Velasco, N., A. Dominguez and M.A. Vega, 2004. Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands. Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem. Pharmacol., 67: 303-313.
CrossRef  |  

76:  Sadeghi, M.M., M. Collinge, R. Pardi and J.R. Bender, 2000. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: Involvement of an inhibitory G protein. J. Immunol., 165: 2712-2718.
Direct Link  |  

77:  Choudhury, R.P., L.A. Carrelli, J.D. Stern, I. Chereshnev and R. Soccio et al., 2004. Effects of simvastatin on plasma lipoproteins and response to arterial injury in wild-type and apolipoprotein-E-deficient mice. J. Vascular Res., 41: 75-83.
CrossRef  |  

78:  Wang, Y.X., B. Martin-McNulty, L.Y. Huw, V. da Cunha and J. Post et al., 2002. Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis, 162: 23-31.
Direct Link  |  

79:  Al-Shali, K.Z. and R.A. Hegel, 2004. Laminopathies and atherosclerosis. Arterioscler. Thromb. Vascular Biol., 24: 1591-1595.
Direct Link  |  

80:  Mortensen, S.A., 2000. Coenzyme Q10 as an adjunctive therapy in patients with congestive heart failure. J. Am. College Cardiol., 36: 304-305.
Direct Link  |  

81:  Diebold, B.A., N.V. Bhagavan and R.J. Guillory, 1994. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs. Biochim. Biophys. Acta, 1200: 100-108.

82:  Ichihara, K., K. Satoh and Y. Abiko, 1993. Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs. J. Cardiovasc. Pharmacol., 22: 852-856.

83:  Satoh, K. and K. Ichihara, 2000. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J. Cardiovasc. Pharmacol., 35: 256-262.
Direct Link  |  

84:  Ichihara, K. and K. Satoh, 2002. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet, 359: 2195-2198.
Direct Link  |  

85:  Marz, W., R. Siekmeier, H.M. Muller, H. Wieland, W. Gross and H.G. Olbrich, 2000. Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J. Cardiovasc. Pharmacol. Therapeut., 5: 275-279.
CrossRef  |  

86:  Simko, F., J. Matuskova, I. Luptak, K. Krajcirovicova and J. Kucharska et al., 2004. Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci., 74: 1211-1224.
Direct Link  |  

87:  Silver, M.A., P.H. Langsjoen, S. Szabo, H. Patil and A. Zelinger, 2004. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am. J. Cardiol., 94: 1306-1310.
PubMed  |  

88:  Sever, P.S., B. Dahlof, N.R. Poulter, H. Wedel and G. Beevers et al., 2003. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet, 361: 1149-1158.
PubMed  |  

89:  De Lorgeril, M., P. Salen, L. Bontemps, P. Belichard, A. Geyssant and R. Itti, 1999. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J. Cardiovasc. Pharmacol., 33: 473-478.

90:  Laufs, U., M. Endres, F. Custodis, K. Gertz, G. Nickenig, J.K. Liao and M. Bohm, 2000. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation, 102: 3104-3110.
PubMed  |  

91:  Puccetti, L., A.L. Pasqui, M. Pastorelli, G. Bova and M. Di-Renzo et al., 2003. Platelet hyperactivity after statin treatment discontinuation. Thromb. Haemost., 90: 476-482.
Direct Link  |  

92:  Brandes, R.P., S. Beer, T. Ha and R. Busse, 2003. Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells. Arterioscler. Thromb. Vascular Biol., 23: 1794-1800.
Direct Link  |  

93:  Lee, K.T., W.T. Lai, C.S. Chu, L.Y. Tsai, H.W. Yen, W.C. Voon and S.H. Sheu, 2004. Effect of withdrawal of statin on C-reactive protein. Cardiology, 102: 166-170.
CrossRef  |  

94:  Laufs, U., S. Wassmann, S. Hilgers, N. Ribaudo, M. Bohm and G. Nickenig, 2001. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am. J. Cardiol., 88: 1306-1307.
PubMed  |  

95:  Heeschen, C., C.W. Hamm, U. Laufs, S. Snapinn, M. Bohm and H.D. White, 2002. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation, 105: 1446-1452.
CrossRef  |  

96:  Montero, M.T., O. Hernandez, Y. Suarez, J. Matilla and A.J. Ferruelo et al., 2000. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis, 153: 303-313.
Direct Link  |  

97:  Houten, S.M., J. Frenkel and H.R. Waterham, 2003. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol. Life Sci., 60: 1118-1134.
PubMed  |  

98:  Sinzinger, H., 2002. Flu-like response on statins. Med. Sci. Monit., 8: CR384-388.
PubMed  |  

99:  Noel, B., 2004. Autoimmune disease and other potential side-effects of statins. Lancet, 363: 2000-2000.
Direct Link  |  

100:  Hakamada-Taguchi, R., Y. Uehara, K. Kuribayashi, A. Numabe and K. Saito et al., 2003. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circulation Res., 93: 948-956.
Direct Link  |  

101:  Narayan, S., N. Hawley, P. Giguere and A.D. Badley, 2003. Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors. HIV Clin. Trials, 4: 164-169.
CrossRef  |  

102:  Loike, J.D., D.Y. Shabtai, R. Neuhut, S. Malitzky and E. Lu et al., 2004. Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol. Arterioscler. Thromb. Vascular Biol., 24: 2051-2056.
Direct Link  |  

103:  Sniderman, A.D., 2004. Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am. J. Cardiol., 94: 30F-34F.
PubMed  |  

104:  De Denus, S., S.A. Spinler, K. Miller and A.M. Peterson, 2004. Statins and liver toxicity: A meta-analysis. Pharmacotherapy, 24: 584-591.
PubMed  |  

105:  Nakad, A., L. Bataille, V. Hamoir, C. Sempoux and Y. Horsmans, 1999. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet, 353: 1763-1764.

106:  Smith, P.F., R.S. Eydelloth, S.J. Grossman, R.J. Stubbs and M.S. Schwartz et al., 1991. HMG-CoA reductase inhibitor-induced myopathy in the rat: Cyclosporine A interaction and mechanism studies. J. Pharmacol. Exp. Therapeut., 257: 1225-1235.
Direct Link  |  

107:  Gershovich, O.E. and A.E. Lyman, 2004. Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature. Pharmacotherapy, 24: 150-154.
CrossRef  |  

108:  Tolman, K.G., 2002. The liver and lovastatin. Am. J. Cardiol., 89: 1374-1780.
CrossRef  |  

109:  Chalasani, N., H. Aljadhey, J. Kesterson, M.D. Murray and S.D. Hall, 2004. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology, 126: 1287-1292.
PubMed  |  

110:  Goalstone, M.L., K. Wall, J.W. Leitner, T. Kurowski and N. Ruderman et al., 1999. Increased amounts of farnesylated p21Ras in tissues of hyperinsulinaemic animals. Diabetologia, 42: 310-316.

111:  McCarty, M.F., 2002. Insulin's stimulation of endothelial superoxide generation may reflect up-regulation of isoprenyl transferase activity that promotes rac translocation. Med. Hypotheses, 58: 472-475.
Direct Link  |  

112:  Martinez-Gonzalez, J., M. Vinals, F. Vidal, V. Llorente-Cortes and L. Badimon, 1997. Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis, 135: 213-223.

113:  Tomiyama, K., E. Nishio and Y. Watanabe, 1999. Both wortmannin and simvastatin inhibit the adipogenesis in 3T3-L1 cells during the late phase of differentiation. Jpn. J. Pharmacol., 80: 375-378.

114:  Chamberlain, L.H., 2001. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett., 507: 357-361.
Direct Link  |  

115:  Kanda, M., K. Satoh, K. Ichihara, 2003. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol. Pharm. Bull., 26: 1681-1684.
PubMed  |  

116:  Jula, A., J. Marniemi, R. Huupponen, A. Virtanen, M. Rastas and T. Ronnemaa, 2002. Effects of diet and simvastatin on serum lipids, insulin and antioxidants in hypercholesterolemic men: A randomized controlled trial. J. Am. Med. Assoc., 287: 598-605.

117:  Sacks, F.M., M.A. Pfeffer, L.A. Moye, J.L. Rouleau and T.G. Cole et al., 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335: 1001-1009.
CrossRef  |  PubMed  |  Direct Link  |  

118:  Shepherd, J., G.J. Blauw, M.B. Murphy, E.L. Bollen and B.M. Buckley et al., 2002. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet, 360: 1623-1630.

119:  Lewis, S.J., F.M. Sacks, J.S. Mitchell, C. East and S. Glasser et al., 1998. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The cholesterol and recurrent events (CARE) trial. J. Am. College Cardiol., 32: 140-146.

120:  Beck, P., D.K. Wysowski, W. Downey and D. Butler-Jones, 2003. Statin use and the risk of breast cancer. J. Clin. Epidemiol., 56: 280-285.

121:  Portakal, O., O. Ozkaya, M.E. Inal, B. Bozan, M. Kosan and I. Sayek, 2000. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin. Biochem., 33: 279-284.
PubMed  |  

122:  Sinatra, S.T., 1999. Care, cancer and coenzyme Q10. J. Am. College Cardiol., 33: 897-899.

123:  Muscaritoli, M., P. Costelli, M. Bossola, G. Grieco and G. Bonelli et al., 2003. Effects of simvastatin administration in an experimental model of cancer cachexia. Nutrition, 19: 936-939.

124:  Brewer, H.B., 2003. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am. J. Cardiol., 92: 23K-29K.
CrossRef  |  

125:  Agarwal, R., 2004. Statin induced proteinuria: Renal injury or renoprotection? J. Am. Soc. Nephrol., 15: 2502-2503.

126:  Sidaway, J.E., R.G. Davidson, F. McTaggart, T.C. Orton, R.C. Scott, G.J. Smith and N.J. Brunskill, 2004. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J. Am. Soc. Nephrol., 15: 2258-2265.

127:  Verhulst, A., P.C. D'Haese and M.E. de Broe, 2004. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J. Am. Soc. Nephrol., 15: 2249-2257.

128:  Rao, P.V., W.G. Robison, F. Bettelheim, L.R. Lin, V.N. Reddy and J.S. Zigler, 1997. Role of small GTP-binding proteins in lovastatin-induced cataracts. Invest. Ophthalmol. Visual Sci., 38: 2313-2321.
Direct Link  |  

129:  Cheng, Q., W. Gerald Robison and J.S. Zigler, 2002. Geranylgeranyl pyrophosphate counteracts the cataractogenic effect of lovastatin on cultured rat lenses. Exp. Eye Res., 75: 603-609.

130:  Cenedella, R.J., J.R. Kuszak, K.J. Al-Ghoul, S. Qin and P.S. Sexton, 2003. Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats. J. Lipid Res., 44: 198-211.
Direct Link  |  

131:  Schlienger, R.G., W.E. Haefeli, H. Jick and C.R. Meier, 2001. Risk of cataract in patients treated with statins. Arch. Int. Med., 161: 2021-2026.
PubMed  |  

132:  Smeeth, L., R. Hubbard and A.E. Fletcher, 2003. Cataract and the use of statins: A case-control study. QJM, 96: 337-343.
Direct Link  |  

133:  Edison, R.J. and M. Muenke, 2004. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N. Engl. J. Med., 350: 1579-1582.

134:  Jackson, P.R., E.J. Wallis, I.U. Haq and L.E. Ramsay, 2001. Statins for primary prevention: At what coronary risk is safety assured? Br. J. Clin. Pharmacol., 52: 439-446.

©  2022 Science Alert. All Rights Reserved